Login
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC.

madrigalpharma.com

What Do They Do?

Sells Rezdiffra, an oral medicine for adults with a form of liver disease, and develops other potential treatments for that disease.

Who Are Their Customers?

The company sells Rezdiffra to specialty pharmacies and specialty distributors, which deliver the medicine to patients in the United States.

Customers above 10% of revenue, FY2025
of revenue from four customers (34%, 22%, 15%, 12%)
FY2024: 86% from four customers

Do Revenues Turn Into Profits?

No. It lost $288.3M in FY2025.

Operating income, FY2025
−31% of revenue
▲ +40% (Loss) vs FY2024 (−$497.9M, −276%)
Net income, FY2025
−30% of revenue
▲ +38% (Loss) vs FY2024 (−$465.9M, −259%)
Free cash flow, FY2025
−20% of revenue
▲ +58% (Loss) vs FY2024 (−$457M, −254%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +50%
vs $287.3M in Q3 FY2025
  • Jul 30, 2026 MGL-2086 entered Phase 1 testing The company began dosing healthy volunteers in a trial supporting development of a Rezdiffra combination treatment.

From development to sales The older report described Madrigal as clinical-stage, with resmetirom as its lead product candidate. The latest report describes Rezdiffra as an approved and commercially sold medicine, alongside a pipeline of additional MASH candidates.

Who Do They Compete With?

Competes with Novo Nordisk, Inventiva, Roche, Eli Lilly, and Boehringer Ingelheim International

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support